Literature DB >> 9371599

Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus.

G Moraleda1, J Saputelli, C E Aldrich, D Averett, L Condreay, W S Mason.   

Abstract

The template for synthesis of hepadnaviral RNAs is a covalently closed circular (ccc) DNA located in the nucleus of the infected hepatocyte. Hepatocytes are normally long-lived and nondividing, and antiviral therapies in chronically infected individuals face the problem of eliminating not only the replicative forms of viral DNA found in the cytoplasm but also the cccDNA from the nucleus. Because cccDNA does not replicate semiconservatively, it is not an obvious target for antiviral therapy. However, elimination of cccDNA might be facilitated if its half-life were short in comparison to the generation time of hepatocytes and if new cccDNA formation were effectively blocked. We have therefore measured cccDNA levels in woodchuck hepatocyte cultures following in vitro infection with woodchuck hepatitis virus and treatment with inhibitors of viral DNA synthesis. The viral reverse transcriptase inhibitors lamivudine (3TC) [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine), FTC (5-fluoro-2',3'-dideoxy-3'-thiacytidine) and ddC (2',3'-dideoxycytidine) were added to the cultures beginning at 4 days postinfection. Treatment for up to 36 days with 3TC reduced the amount of cccDNA in the cultures not more than twofold compared to that of an untreated control. Treatment with ddC for 36 days and with FTC for 12 days resulted in effects similar to that of treatment with 3TC. Moreover, the declines in cccDNA appeared to reflect the loss of hepatocytes from the cultures rather than of cccDNA from hepatocytes. These results emphasize the important role of the longevity of the infected hepatocytes in the persistence of an infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371599      PMCID: PMC230243     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl-paper and rapid hybridization by using dextran sulfate.

Authors:  G M Wahl; M Stern; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

2.  A simple, rapid, and sensitive DNA assay procedure.

Authors:  C Labarca; K Paigen
Journal:  Anal Biochem       Date:  1980-03-01       Impact factor: 3.365

3.  Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate.

Authors:  J Summers; W S Mason
Journal:  Cell       Date:  1982-06       Impact factor: 41.582

4.  Early events in duck hepatitis B virus infection. Sequential appearance of viral deoxyribonucleic acid in the liver, pancreas, kidney, and spleen.

Authors:  M Tagawa; M Omata; O Yokosuka; K Uchiumi; F Imazeki; K Okuda
Journal:  Gastroenterology       Date:  1985-12       Impact factor: 22.682

5.  Core antigen and antibody in woodchucks after infection with woodchuck hepatitis virus.

Authors:  A Ponzetto; P J Cote; E C Ford; R H Purcell; J L Gerin
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

6.  Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells.

Authors:  J S Tuttleman; C Pourcel; J Summers
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

7.  Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression.

Authors:  C Luscombe; J Pedersen; E Uren; S Locarnini
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

8.  Experimental transmission of duck hepatitis B virus.

Authors:  W S Mason; M S Halpern; J M England; G Seal; J Egan; L Coates; C Aldrich; J Summers
Journal:  Virology       Date:  1983-12       Impact factor: 3.616

9.  Hepatitis B virus DNA forms in nuclear and cytoplasmic fractions of infected human liver.

Authors:  R H Miller; W S Robinson
Journal:  Virology       Date:  1984-09       Impact factor: 3.616

10.  Nucleotide sequence of a cloned woodchuck hepatitis virus genome: evolutional relationship between hepadnaviruses.

Authors:  K Kodama; N Ogasawara; H Yoshikawa; S Murakami
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

View more
  87 in total

1.  Low dynamic state of viral competition in a chronic avian hepadnavirus infection.

Authors:  Y Y Zhang; J Summers
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine.

Authors:  T Zhou; J Saputelli; C E Aldrich; M Deslauriers; L D Condreay; W S Mason
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.

Authors:  W E Delaney; T G Miller; H C Isom
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

4.  Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication.

Authors:  William R Addison; Kathie-Anne Walters; Winnie W S Wong; John S Wilson; Danuta Madej; Lawrence D Jewell; D Lorne J Tyrrell
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 6.  Immune escape by hepatitis B viruses.

Authors:  U Protzer; H Schaller
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

Review 7.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

Review 8.  Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.

Authors:  Ju-Tao Guo; Haitao Guo
Journal:  Antiviral Res       Date:  2015-08-10       Impact factor: 5.970

9.  Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.

Authors:  Jung Woo Shin; Neung Hwa Park; Seok Won Jung; Byung Chul Kim; Sung Ho Kwon; Jae Serk Park; In Du Jeong; Sung-Jo Bang; Do Ha Kim
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

10.  Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1alpha-null HBV transgenic mice.

Authors:  Aimee L Anderson; Krista E Banks; Marco Pontoglio; Moshe Yaniv; Alan McLachlan
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.